Phosphatase and Tensin Homolog in Non-neoplastic Digestive Disease: More Than Just Tumor Suppressor

Tianyu He†, Xiaoyun Zhang‡, Jianyu Hao‡ and Shigang Ding* *

1 Department of Gastroenterology, Peking University Third Hospital, Beijing, China, 2 Department of Gastroenterology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

The Phosphatase and tensin homolog (PTEN) gene is one of the most important tumor suppressor genes, which acts through its unique protein phosphatase and lipid phosphatase activity. PTEN protein is widely distributed and exhibits complex biological functions and regulatory modes. It is involved in the regulation of cell morphology, proliferation, differentiation, adhesion, and migration through a variety of signaling pathways. The role of PTEN in malignant tumors of the digestive system is well documented. Recent studies have indicated that PTEN may be closely related to many other benign processes in digestive organs. Emerging evidence suggests that PTEN is a potential therapeutic target in the context of several non-neoplastic diseases of the digestive tract. The recent discovery of PTEN isoforms is expected to help unravel more biological effects of PTEN in non-neoplastic digestive diseases.

Keywords: PTEN, tumor suppressor, PI3K/AKT pathway, digestive organs, infection, inflammation, fibrosis

INTRODUCTION

Phosphatase and tensin homolog (PTEN) gene, located on chromosome 10q23, was identified as a tumor suppressor gene approximately 20 years ago (Li et al., 1997). This gene modulates a wide range of biological processes by acting on both phosphoinositide and polypeptide substrates via multiple signaling pathways such as phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) (Maehama and Dixon, 1998; Manning and Cantley, 2007).
and Ras/Raf/MEK/ERK (Hettinger et al., 2007). In addition, PTEN also acts through other non-enzymatic mechanisms. The phosphatase independent activity of PTEN contributes to the chromosomal stability and double-strand DNA breaks repair (Milella et al., 2015). Dysregulation of PTEN and its downstream signaling molecules may lead to abnormal cellular processes such as aberrant proliferation, abnormal survival, metabolism disorder, anomalous motility, and carcinogenesis.

Tumor, inflammation, infection, metabolic abnormalities, and fibrosis are common characteristics of organic diseases of the digestive system. PTEN mutation, PTEN loss, or its inactivity has been documented in the context of several cancers of the digestive tract (Eng, 2003; Bettstetter et al., 2013). However, since PTEN modulates a variety of biological processes, an increasing number of studies have investigated the changes in PTEN in the context of non-neoplastic digestive diseases such as hepatitis, colitides, pancreatitis, hepatic insulin resistance, and liver fibrosis. These studies have partially unraveled the potential role of PTEN and its dual phosphatase activity in non-neoplastic digestive diseases and the associated underlying mechanisms. In order to characterize the potential role of PTEN in the treatment of benign diseases, we reviewed the contemporary literature pertaining to PTEN protein published in the last decade, and highlight the potential role of PTEN in non-neoplastic digestive diseases.

**STRUCTURE AND ACTIVITY OF PTEN PROTEIN**

PTEN protein consists of 403 amino acids and is encoded by the PTEN gene located on chromosome 10q23.31 (Li et al., 1997). Crystallographic analysis conducted in 1999 revealed its five functional domains, i.e., an N-terminal phosphatidylinositol (PtdIns) (4,5) P_2-binding domain (PBD), a phosphatase domain, a C2 lipid or membrane-binding domain, a carboxy-terminal tail, and a class I PDZ-binding (PDZ-BD) motif (Figure 1; Lee et al., 1999). The N-terminal domain is the main functional region of PTEN, which is homologous to tensin and auxilin, and is responsible for regulating the phosphatase activity by forming a wide substrate-binding pocket (Maehama and Dixon, 1998; Walker et al., 2004). The C-terminal domain is responsible for the activity, stability, and cellular localization of PTEN by regulating protein-protein interactions (Vazquez et al., 2000; Raftopoulou et al., 2004).

Phosphorylation of the C-terminal tail regulates the conformation of PTEN, which can affect the activity and stability of the PTEN protein. Unlike most proteins, the changes in PTEN function after phosphorylation may seem contradictory. Phosphorylation of S370 and cluster Ser380, Thr383, and Ser385 in the tail increases the stability of the protein and renders it less active (Fragoso and Barata, 2015). However, tail-deficient in PTEN causes loss of stability and confers phosphatase activity (Vazquez et al., 2000). This phenomenon has been shown to be associated with the transformation of closed and open conformation. The closed conformation is attributed to C-terminal phosphorylation, which promotes the interaction between acidic tail and C2 domain, and appears to increase stability but decrease lipid phosphatase activity via inhibiting membrane binding of PTEN (Vazquez et al., 2001). In the open conformation, dephosphorylation of PTEN reverses this change, and allows PTEN recruitment to the membrane and its binding to the PDZ domain-containing proteins (Chia et al., 2015).

Two recent studies have suggested PTEN dimerization as a new working model for the function of PTEN protein (Papa et al., 2014; Heinrich et al., 2015). The homo-dimeric PTEN complexes are critical for the lipid phosphatase function of PTEN and are more active than PTEN monomer in PIP3 dephosphorylation. However, the hetero-dimerization of cancer-associated PTEN mutants with wildtype PTEN has a dominant negative effect in cancer (Papa et al., 2014). The underlying mechanism for this phenomenon was revealed by another study which found PTEN homo-dimers in vitro. Dephosphorylation of the PTEN-tail, which confers it a more open conformation, was shown to allow dimerization and stabilize the homo-dimer (Heinrich et al., 2015). These findings provide insights into the cellular function and the molecular mechanism of PTEN activity regulation, which may provide a novel approach for cancer prevention and treatment.

**BIOLOGICAL FUNCTIONS AND REGULATION OF PTEN**

With dual specific phosphatase activity, PTEN protein acts on both phosphoinositide and polypeptide substrates. Phosphatidylinositol (PtdIns) (4,5) P_2, a component of the lipid membrane, is considered to be the main substrate of PTEN (Maehama and Dixon, 1998). Dephosphorylation of this lipid substrate induces an inhibitory effect of PTEN on the PI3K-AKT-mTOR signaling pathway which is involved in cell growth, proliferation, survival, and metabolism (Manning and Cantley, 2007; Lee et al., 2018). In addition, PTEN can also cause dephosphorylation of some protein substrates, including focal adhesion kinase 1 (FAK), Shc, insulin receptor substrate-1 (IRS1), and cAMP-responsive element-binding protein 1 (CREB1) (Gu et al., 1999, 2011; Schneider et al., 2011; Shi et al., 2014). As both FAK and Shc are involved in integrin signaling, inhibition of their tyrosine phosphorylation by PTEN suppresses the integrin-mediated cell migration, which is independent of its effect on the PI3K/AKT pathway (Schneider et al., 2011; Zhang et al., 2014). Besides, PTEN selectively dephosphorylates IRS1, a mediator in insulin signaling, which plays a key role in metabolic diseases (Shi et al., 2014). Despite the discovery of an increasing number of polypeptide substrates of PTEN, further studies are required to characterize the biological roles of the dual phosphatase activity of the PTEN protein.

In addition to cytoplasm, PTEN is also found in nucleus, mitochondria, and endoplasmic reticulum (ER). The nuclear pool of PTEN is generally believed to exert its effects in a lipid phosphatase-independent way (Lindsay et al., 2006). Nuclear PTEN has been shown to play a role in DNA repair and maintenance of genomic stability (Shen et al., 2007). Additionally, it may also act as a pro-apoptotic factor by regulating cell
PTEN for in-depth characterization of the role of the tumorigenesis process. Therefore, further studies are required indicates that PTEN gene may act like a double-edged sword in induce activation of relative oncogenes (Shen et al., 2019). This not regulation of AKT, to promote trimethylation of H3K4 and modifications, transcriptional post-transcriptional regulation, and post-translational regulation.

As a tumor suppressor gene, genetic loss or mutations of PTEN have been demonstrated in many primary human cancers and cancer cell lines (Guldberg et al., 1997; Ying et al., 2011). Early studies have demonstrated germline mutations of PTEN gene in PTEN hamartomatous tumor syndrome and Cowden syndrome; subsequently, more novel mutations have gradually been discovered in recent years (Liaw et al., 1997; Seol et al., 2015; Williams et al., 2018). Additionally, epigenetic modifications (such as DNA methylation and histone acetylation) may also regulate the expression of PTEN. PTEN loss caused by aberrant hypermethylation of the DNA promoter region has been identified in various malignant and benign (non-tumor) diseases (Mueller et al., 2012; Zhang et al., 2016; Geybels et al., 2017). Moreover, histone acetylation induced by the interaction of transcription factor SAL-like protein 4 and NuRD (a histone deacetylase repressor complex) at the promoter region can regulate PTEN transcription (Lu et al., 2009). In addition, inhibition of histone deacetylase (HDAC) has been shown to suppress the growth and invasion of cancer cells, which may provide a basis for novel anticancer therapies (Meng et al., 2016; Qian et al., 2018). Various transcription factors can upregulate or downregulate the expression of PTEN via multiple signaling pathways. For instance, p53, early growth response 1 (EGR1), and peroxisome proliferators activated receptor γ (PPARγ) can activate PTEN transcription via directly binding to the promoter region of PTEN (Stambolic et al., 2001; Lee et al., 2006; Kim et al., 2014); on the contrary, the ecotropic virus integration site 1 protein homologue (EVII), B-lymphoma Mo-MLV insertion region 1 (BMI1) protein, and Ras/Raf/MEK/ERK pathway were shown to play a role in suppressing PTEN expression (Song et al., 2009; Yoshimi et al., 2011; Ciuffreda et al., 2012). Furthermore, at the post-transcriptional level, PTEN mRNA is regulated by microRNAs (miRNA; miRNA-21, -32, and -106b) (Wu et al., 2013, 2017c; Yang et al., 2014) and Long non-coding RNAs (LncRNA; LncRNA FER1L4, MEG3, and GASS, etc.) (Qiao and Li, 2016; Gao et al., 2017; Yang et al., 2018). Moreover, some of the miRNAs and LncRNAs participate in the complex competing endogenous RNAs (ceRNAs) networks, represented by the mRNA of PTEN pseudogene 1 (PTENP1) and Versican

![Schematic illustration of the structure of the PTEN protein.](image-url)
He et al. PTEN in Non-neoplastic Digestive Diseases

FIGURE 2 | PTEN expression in the pathological process of digestive system diseases. Aberrant PTEN expression is implicated in several diseases of the digestive system. Gene mutation, translational or post-translational regulation is involved in the pathological process. EACs, esophageal adenocarcinomas; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; CRC, colorectal carcinoma; HCC, hepatocellular carcinoma; IBD, inflammatory bowel disease; AP, acute pancreatitis; NAFLD, non-alcoholic fatty liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus; Hp, helicobacter pylori.

PTEN AND NON-NEOPLASTIC DIGESTIVE DISEASE

The protein encoded by the PTEN gene is ubiquitous in the human body, including in the organs of the digestive system. As a critical tumor suppressor, mutation or deficiency of PTEN gene contributes to tumorigenesis in the digestive system, including esophageal carcinoma (Eng, 2003), gastric cancer (GC) (Wadhwa et al., 2013), colorectal carcinoma (CRC) (Ling et al., 2015), hepatocellular carcinoma (HCC) (Horie et al., 2004), pancreatic cancer (Ni et al., 2017), gall bladder cancer (Roa et al., 2015), and cholangiocarcinoma (Lee et al., 2012). However, studies conducted in recent years have demonstrated the regulatory role of PTEN in non-neoplastic diseases of the digestive system (Figure 2). It is increasingly being acknowledged that the biological role of PTEN in the pathogenesis of non-neoplastic digestive diseases may be mediated via mechanisms other than the dephosphorylation of PIP3 (Figure 3). In particular, many miRNAs and LncRNAs have been found to regulate the expression of PTEN in the pathogenesis of digestive system diseases (Table 1), laying an increasing emphasis on their role in gene regulation.

PTEN in Infectious Diseases of Gut Hepatitis B and C Virus Infection

Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are major causes of viral hepatitis, and contributors to the incidence of HCC. Hepatitis virus induces dysregulation of hepatocyte metabolism; in addition, immune evasion of these viruses contributes to the development of chronic virus infection. Several studies have indicated the involvement of PTEN in these processes.

HBV X protein (HBx) is a key regulatory protein among the four proteins encoded by the HBV genome. Although HBx does not directly bind to the DNA, it influences the transcriptional activity of genes through interacting with the transcription factors or molecules of signaling pathways in host cells (Park et al., 2020). PI3K/AKT is one of the pathways activated by HBx, which regulates cell proliferation, cell death, and survival. Therefore, HBx is believed to play a pivotal role in the pathogenesis of HCC (Chung et al., 2004). PTEN is a specific inhibitor in the PI3K/AKT pathway; HBx downregulates PTEN, which promotes the proliferation and migration of liver cancer cells (Tu et al., 2019). Studies have identified several mechanisms by which HBx regulates the PTEN gene, including by influencing the epigenetic alterations of PTEN gene promoter, upregulating PTEN-targeted miRNAs (miRNA-21, miR-19a, miR-29a), and by promoting the production of reactive oxygen species (ROS) to inactivate PTEN (Ha and Yu, 2010; Kong et al., 2011; Um et al., 2011; Yu et al., 2016; Hou and Quan, 2017). Due to the regulation and alteration of the pro-apoptotic ability of PTEN by HBx, CRISPR/Cas9-mediated p53, and Pten somatic mutation was shown to accelerate hepatocarcinogenesis in adult HBV transgenic mice (Liu et al., 2017). In addition, PTEN has also
FIGURE 3 | The role of dual phosphatase activity of PTEN in non-neoplastic digestive diseases. PTEN acts in regulating a wide spectrum of biological functions. The above summarizes the biological role of PTEN in the pathogenesis of non-neoplastic digestive diseases via lipid or protein phosphatase activity. HBV, hepatitis B virus; HCV, hepatitis C virus; Hp, helicobacter pylori; AP, acute pancreatitis; NAFLD, non-alcoholic fatty liver disease; HSC, hepatic stellate cells; PSCs, pancreatic stellate cells; CgA, chromogranin A; EECs, enteroendocrine cells; PI3K, phosphatidylinositol 3-kinase; FAK, focal adhesion kinase 1; IRS1, insulin receptor substrate-1.

been considered as a potential prognostic marker in patients with virus-induced HCC (Khalid et al., 2017). In addition, the interactions between PTEN polymorphisms and HBV mutations may help identify individuals who are susceptible to HCC (Du et al., 2015). HBx and HBV polymerase (HBp) were shown to enhance PD-L1 expression through PTEN-dependent pathway, which induces inhibition of T cell response and promotes virus immune evasion in mice (Sun et al., 2020).

PTEN is also a target pathogenic pathway of hepatitis C virus core protein. HCV core protein, an important agent related to HCC, can inhibit PTEN expression and promote virion egress (Clément et al., 2019). Studies have demonstrated that the dual phosphatase activity of PTEN has a protective effect against HCV infection by acting at different stages of its pathogenesis. The lipid phosphatase activity of PTEN inhibits HCV entry, while the protein phosphatase activity of PTEN helps decrease HCV replication through the interaction between domain I of HCV core and PTEN residues. In addition, HCV infection in turn increases the lipid phosphatase activity of PTEN (Wu et al., 2017b). In human hepatocyte-engrafted (MUP-uPA/SCID/Bg) mice model, PTEN depletion was shown to play an important role in the initiation of HCV infection-associated HCC (Wang et al., 2015b). Based on the role of PTEN in the process of HCV infection, PTEN-Long, a translation isoform of PTEN, may inhibit HCV replication by interacting with the HCV core protein (Wu et al., 2017a). Therefore, exogenous administration of PTEN is a potential therapeutic strategy against viral hepatitis.

Helicobacter pylori Infection
Helicobacter pylori (H. pylori) infection is the main risk factor for GC. Chronic H. pylori infection contributes to chronic non-atrophic gastritis, which eventually develops into dysplasia and ultimately GC. Only a few studies have focused on the involvement of PTEN in H. pylori infection. GC patients with H. pylori infection showed significantly decreased expression of PTEN gene in serum as compared to healthy volunteers; this suggested a potential role of PTEN gene in GC patients with H. pylori infection (Ranjbar et al., 2018). A series of studies
investigating the role of PTEN in the pathogenesis of *H. pylori* infection yielded interesting findings. First, phosphorylation of PTEN at residues Ser380/Thr382/383 induced by *H. pylori* was found to promote the survival of gastric epithelial cells, since the PTEN phosphorylation correlates with the activation of the PI3K/AKT pathway (Yang et al., 2017). Subsequently, PLK1 was found to influence p-PTEN level, which may be involved in the early stage of *H. pylori*-induced GC (Xu et al., 2018). Another study also found that *H. pylori* can promote cell invasion via phosphorylation of PTEN and activation of FAK (Yang et al., 2018). Further studies are required to clarify the mechanisms of PTEN regulation in *H. pylori* infection and *H. pylori*-induced GC.

**Salmonella Infection**

*Salmonella enterica* (Gram-negative enteropathogenic bacteria) is one of the most common causes of food poisoning. People are generally susceptible to Salmonella, especially infants and elderly people; the clinical manifestations depend on the virulence of the strain and the immune status of the host (Kurtz et al., 2017). PTEN has been considered vital for Toll-like receptor (TLR) 5-induced immune and inflammatory responses in the intestinal epithelial cells (IECs). PTEN deficiency in IECs can increase the susceptibility to Salmonella infection (Howe et al., 2019). Besides, when challenged with Salmonella infection, PTEN was epigenetically suppressed by CUL4B, which negatively regulates the TLR-triggered signaling and maintains the anti-inflammatory pathway PI3K-AKT-glycogen synthase kinase (GSK) 3β. However, overexpression of PTEN caused by CUL4B deletion contributed to excessive activation of GSK3 and uncontrolled immune response, which may increase the risk of septic shock in infected individuals (Song et al., 2021).

*Salop*B is an important modulator of signal transduction with phosphatase activity in host cells during Salmonella infection. *Salop*B activates pro-survival kinase Akt, which optimizes bacterial replication in host, while PTEN can inhibit Akt activation during Salmonella invasion (Roppenser et al., 2013). These findings indicate a vital role of PTEN in the process of Salmonella infection, including in determining the susceptibility to bacterial invasion and modulating the inflammatory response in host cells. However, further studies are required to unravel the precise mechanism of the involvement of PTEN in these processes.

**PTEN in Inflammation Disease of Gut Colitides**

Colitides is a generic term used to describe inflammatory diseases of colon, including inflammatory bowel disease (IBD)—associated colitis and non-IBD forms of colitis (such as microscopic colitis, radiation colitis, eosinophilic colitis, and ischemic colitis). PTEN is believed to play an important role in the inflammation...
associated with collagenous colitis (Norén et al., 2018) and IBD (Li et al., 2013), as PTEN deficiency has been documented during this process. Upregulation of interleukin (IL)-6 was shown to induce STAT3-mediated miR-214 expression in active ulcerative colitis (UC). miR-214 was shown to activate and amplify the inflammatory response through a feedback loop mediated by PTEN and PDZ and LIM domain 2 (PDLIM2) suppression, and with increased AKT phosphorylation and NF-κb activation (Polyarchou et al., 2015). A recent study conducted in miR-26a myeloid-cell-specific overexpression mice showed that miR-26a attenuates the intestinal inflammatory response in macrophages by inhibiting the activation of NF-κb/STAT3 and decreasing the production of IL-6. In addition, PTEN was identified as one of the potential targets of miR-26a (Zhang W. et al., 2021). The above findings indicate that PTEN reduction may contribute to the circuit activation and persistent inflammatory response in UC and even progression to CRC.

Mutation of gene encoding IL-10 is believed to play a role in the pathogenesis of early onset UC which is characterized by severe colitis in infancy and early childhood. IL-10(−/−) mice were shown to develop spontaneous colitis in the presence of intestinal microbiota; in addition, disruption or inhibition of PTEN was found to increase the severity of colitis and influence colitogenic bacteria in these mice. Due to the impact of PTEN on important cell functions and TLR signaling, disruption of PTEN in the intestinal epithelium of IL-10(−/−) mice hastened the occurrence of severe colitis. Moreover, increased abundance of Bacteroides species was detected in fecal microbiota of PTEN loss IL-10(−/−) mice (Im et al., 2014). On the other hand, inhibition of PTEN function in IL-10(−/−) mice was also shown to enhance the production of inflammatory factors and to increase the proportion of colitogenic bacteria (Bacteroides species) in fecal microbiota (Mitchell et al., 2018). However, on the contrary, PTEN deletion was found to attenuate colonic inflammation in IL-10(−/−) mice. Microbial factors play an essential role in the development of colitis. In a study, flagellin elicited colonic inflammation in IL-10(−/−) mice. However, deletion of PTEN was shown to disrupt Mal-TLR5 interaction and diminish the flagellin-promoted inflammatory responses by impeding Mal localization at the plasma membrane and preventing Mal-TLR5 interaction (Choi et al., 2013). The available evidence suggests that PTEN may mediate the microbe-induced inflammatory immune response in the intestines; however, the specific regulatory mechanisms are not clear.

IBDs are characterized by increased intestinal permeability, which is mainly attributable to the impaired integrity of the tight junctions. Decreased expressions of tight junction-related genes (such as MAGI3, PTEN, and TJPI) were observed in the colonic mucosa of patients with IBD (Norén et al., 2017). These findings support the role of PTEN gene in modulating the intestinal epithelial barrier function in IBD. In addition, increase in the enterendocrine cells (EECs) in mucosa is another manifestation in IBD patients. Pro-inflammatory cytokines promote the number of EECs producing chromogranin A (CgA) along with inactivation of PTEN and increased expression of AKT and autophagy markers in EECs. However, inhibition of AKT and autophagy was found to block the increase in CgA-positive cells (Hernández-Trejo et al., 2016). These findings suggest that PTEN and downstream AKT signaling pathway as well as autophagy regulate the differentiation of EECs during colonic inflammation.

Currently, several drugs that regulate the activity and expression of PTEN are used in the treatment of IBD. 5-aminosalicylic acid (5-ASA), an important drug for treatment of UC, is a potent antioxidant. It can reduce the phosphorylated and oxidized levels of PTEN protein via inducing PPARγ binding to the PTEN promoter; this promotes the activation of PTEN and inhibition of the PI3K/Akt signaling pathway (Managlia et al., 2013). This ultimately reduces the UC-induced ROS in the IECs. In addition, fortunellin, which is isolated from the kumquat fruit, was shown to ameliorate IBD (Vezza et al., 2016). However, contrary to the effects of 5-ASA, fortunellin suppresses the expression of PTEN to reduce epithelial cell apoptosis and ameliorate the symptoms of colitis by targeting miR-374a in rats (Xiong et al., 2018). Chlorogenic acid, an abundant polyphenol in medicinal plants, has been demon-strated to have anti-inflammatory property. Upregulation of PTEN and suppression of Akt and STAT3 expression has been detected in dextran sulfate sodium-induced UC mice model (Vukelić et al., 2018). Thus, regulation of PTEN is a potential therapeutic target for treatment of intestinal inflammation.

**Acute Pancreatitis**

Acute pancreatitis (AP) is a necro-inflammatory disease. Severe acute pancreatitis (SAP) is associated with multiple organ insufficiency and high mortality. A series of studies have focused on the role of miRNAs in AP progression and treatment via regulating PTEN. miR-148a-3p and miR-27a-3p, which are highly expressed in AP, were shown to induce acinar cell apoptosis through targeting PTEN (Cai et al., 2018; Kong et al., 2019). In a mouse model of AP and in rat pancreatic acinar cells, transforming growth factor (TGF)-β was shown to upregulate miR-216a, which inhibited the expressions of PTEN and Smad7 and promoted AP via the PI3K/Akt and TGF-β feedback pathway (Zhang et al., 2015). SAP usually leads to multiple organ dysfunction, especially renal damage. Overexpression of miR-214-3p in a rat model of hyperlipidemic pancreatitis was shown to inhibit PTEN expression and up-regulate the level of P-Akt in kidneys to exacerbate hyperlipidemic pancreatitis with acute renal injury (Yan et al., 2020).

Bone marrow mesenchymal stem cells (BM-MSCs) have an anti-inflammatory effect and showed a protective effect in SAP (Zhao et al., 2016). miR-181a-5p secreted by BM-MSCs reduced the level of angiopoietin, IL-1β, IL-6, and TNFα, and promoted the expressions of IL-4 and IL-10 to alleviate inflammatory response and cell apoptosis by targeting the PTEN/Akt/TGF-β1 pathway (Li H. Y. et al., 2020). Rosiglitazone is widely used for the treatment of diabetes as it increases insulin sensitivity. In recent years, several studies have demonstrated the effects of rosiglitazone on inflammatory response and cell metabolism (Ji et al., 2018). Rosiglitazone was shown to prevent AP by downregulating miR-26a, inhibiting PTEN degradation, and blocking the PI3K/Akt signaling pathway in AP rats (Chen et al., 2019). Thus, an increasing body of evidence has demonstrated...
the important role of the interaction between miRNAs and PTEN in the context of AP, identifying novel potential therapeutic targets for SAP.

PTEN in Metabolic Abnormalities of Digestive Organs

Non-alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases. It is associated with increased risk of type 2 diabetes and cardiovascular diseases (Musso et al., 2011). The term NAFLD encompasses a spectrum of fatty liver diseases including simple steatosis, non-alcoholic steatohepatitis (NASH), and NASH-related fibrosis (Kleiner and Makhoul, 2016). Different from alcoholic liver disease, patients with NAFLD exhibit decreased expression of PTEN in liver tissues; in addition, the degree of downregulation is associated with the percentage of steatosis (Sanchez-Pareja et al., 2016). Furthermore, in mice models, long-term exposure to high-fat diet decreased the PTEN expression in liver and led to mild-to-moderate NAFLD (Nalloor et al., 2017). PTEN deficiency is believed to accelerate the development of NAFLD (Jeong et al., 2018). Knock-down of PTEN in rat liver via CRISPR/Cas-based hydrodynamic injection of pX330-Pten plasmid has been used to construct rat model of NAFLD (Yu Q. et al., 2017).

Hypoxia is one of the factors that aggravate the NAFLD phenotype with increased lipogenesis and inflammation in PTEN-deficient mouse (Byrne, 2009). Another study reported the involvement of spleen in the pathogenesis of NAFLD. Splenectomy was shown to accelerate hepatic steatosis and to increase serum lipid levels through down regulating hepatic PTEN expression and promoting the ratio of pAkt/Akt (Wang et al., 2015a). On the contrary, PTEN upregulation was shown to alleviate NASH. Since miR-146b directly suppresses the IL-1 receptor-associated kinase 1 and tumor necrosis factor receptor-associated factor 6, the downstream molecules NF-kB and PTEN were down and up regulated, and decreased lipid accumulation in the liver cells (Jiang et al., 2015). The above results indicate that PTEN is a potential target for treatment of NAFLD.

Hepatic Insulin Resistance

Glucose homeostasis is achieved by balancing pancreatic insulin secretion with intake or secretion of glucose. Hepatic insulin resistance is defined as the impaired ability of hepatocytes to respond to insulin, which contributes to the progression of type 2 diabetes mellitus (T2DM) and metabolic syndrome (Leclercq et al., 2007). Binding of insulin with the insulin receptor induces tyrosine phosphorylation of insulin receptor substrates (IRS1/2). This process enhances thePIP2 to yield PIP3 via PI3K, which can be inhibited by PTEN. PIP3 contributes to membrane localization of PDK1 and Akt1, and induces Akt1 phosphorylation resulting in glucose uptake and utilization. A recent study showed that phosphorylating IRS-1 at Ser 307 can lead to inhibition of phosphorylation of Akt and GSK-3β and reverse the insulin resistance in HepG2 cells (Malik et al., 2019). Further study revealed the mechanisms by which endosomes activate the hepatic insulin-evoked Akt signaling pathway. The results demonstrated that the binding of IRS 1 and 2 (IRS1/2) and the endosomal insulin receptor (INSR) can promote IRS1/2 phosphorylation and initiate downstream Akt2/GSK-3β and FoxO1 signaling in the liver (Zhang et al., 2020).

Owing to the role of PI3K/Akt signaling in insulin function and glucose metabolism, increased expression of PTEN is believed to promote insulin resistance in liver (Alexandrov et al., 2012; Zuo et al., 2019). A series of studies have revealed aberrant expression of microRNAs associated with insulin resistance through regulating PTEN directly or indirectly. miR-152, which directly targets PTEN expression, was shown to be downregulated in the liver of high fat diet-fed mice, which resulted in increased expression of PTEN and subsequent impaired glycogen synthesis as well as hepatic insulin resistance. The AKT/GSK pathway was found to be involved in this process (Wang et al., 2016). In addition, miR-20a-5p suppresses p63 and in turn binds to p53, diminishing PTEN expression and participates in hepatic glycolgen synthesis by activating AKT and GSK (Fang et al., 2016). However, miR-291b-3p augments PTEN expression and impairs AKT activation by targeting p65, leading to hyperglycemia and hepatic insulin resistance (Guo et al., 2017). A recent study investigated the molecular mechanism of PTEN regulation in balancing insulin action via an oxide transport chain NSAPP. NADPH oxidase-4 (NOX4), a part of insulin signaling NSAPP generates superoxide (O2-) after being stimulated by insulin; NOX4 combines with superoxide dismutase-3 to transfer O2- converting it to hydrogen peroxide. Finally, aquaporin-3 transports H2O2 across the plasma membrane to inactivate PTEN. Thus, disruption of any molecule in the NSAPP chain may lead to persistent PTEN activation and imbalanced insulin action (Wu et al., 2020). In addition to liver, muscle, and adipose tissue, brain has been identified as a new target for insulin and a site for glucose metabolism. Insulin acts on the mediobasal hypothalamus (MBH) to improve the glycometabolism through PI3K activation. In addition, inhibition of PTEN activity in MBH was shown to decrease food intake and weight gain, and also regulate liver insulin resistant independently in high-fat-fed rats (Sumita et al., 2014).

HCV infection was shown to be a risk factor for insulin resistance and T2DM. Owing to the close relationship between viral hepatitis and NAFLD, steatosis is one of the characteristics of HCV infection. HCV genotype 3a core protein was shown to block PTEN translation via miRNA-dependent mechanism. The diminished expression of PTEN in turn led to reduced expression of IRS1 and formation of large lipid droplets (Clément et al., 2011). Similarly, upregulation of PTEN expression was shown to promote insulin sensitivity and reduce the release of proinflammatory factors in mice liver infected with HCV core protein (Jia et al., 2018). However, other studies indicated that liver steatosis is not always associated with insulin sensitivity (Matsumoto et al., 2006; Wu et al., 2012). Oleic acid (OA) was shown to induce hepatic steatosis but with normal insulin sensitivity; this was attributable to activation of the G protein-coupled receptor 40 (GPR40)-phospholipase C (PLC)-calcium pathway by OA and upregulation of PPAR8. PPAR8 further
reduced the expression of PTEN to enhance insulin sensitivity in hepatic steatosis.

**PTEN in Digestive Organ Fibrosis**

**Hepatic Fibrosis**

Hepatic fibrosis, a prominent pathological feature of chronic liver disease, leads to liver cirrhosis, liver failure, and hepatic carcinogenesis. Activation of Kupffer cells (KCs) and hepatic stellate cells (HSCs) plays a pivotal role in this pathogenesis. A growing body of evidence supports the link between PTEN and hepatic fibrosis.

KCs refer to a type of tissue macrophages resident in liver. In a CCl4-induced mouse model of liver fibrosis, KCs showed mixed induction of hepatic classical (M1) and alternative (M2) macrophage markers. PTEN regulates the activation and polarization of M2 macrophages by inhibiting the PI3K/Akt/STAT6 signaling pathway to counteract liver injury (Cheng et al., 2017).

Deposition of extracellular matrix (ECM) caused by the activation of HSCs is a key process in the development of hepatic fibrosis. Hence, identification of potential targets to inhibit the activation of HSCs is a potential strategy for prevention and treatment of hepatic fibrosis. Several recent studies have focused on the role of regulatory non-coding RNAs, such as miRNAs and long intergenic non-coding RNAs (lincRNAs) in the activation of HSCs by affecting PTEN. MiR-21 (Hao et al., 2018), -140-3p (Wu et al., 2019), -141 (Liang et al., 2020), and -1273g-3p (Niu et al., 2016) have been shown to be negative regulators of PTEN, which lead to HSCs activation, cell apoptosis inhibition, and fibrosis formation through regulating the PI3K/Akt or Akt/miTOR pathway. Additionally, Dicer, an enzyme with endonuclease activity, is involved in cutting precursor miRNAs to produce functional forms. Among several miRNAs affected by dicer, miR-138, which targets PTEN, can be downregulated during activation of PSCs and the underlying mechanisms are largely unknown. A study revealed that PTEN inhibition can promote the expression of Mitofusin-2 (Mfn2) and improve mitophagic flux via AMP-activated protein kinase (AMPK)-cAMP-response element-binding protein (CREB) signaling (Li P., et al., 2020). The above findings strongly suggest a role of PTEN in inhibiting hepatic fibrosis. Administration of adenovirus encoding PTEN was shown to decrease collagen deposition in a rat model of liver fibrosis (Xie et al., 2017). This indicated that gene therapy using adenovirus-mediated PTEN is a potential novel therapeutic strategy for liver fibrosis.

**Pancreatic Fibrosis**

Pancreatic fibrosis is a key pathological finding in several pancreatic diseases including chronic pancreatitis, autoimmune pancreatitis, and cystic fibrosis of the pancreas. Activation of pancreatic stellate cells (PSCs) is a key step in the initiation of pancreatic fibrosis. PTEN has recently been recognized as a potential regulatory target for ameliorating pancreatic fibrosis. PTEN protein exhibits dual phosphatase activity. The wildtype PTEN was shown to be more effective than mutant (G129E) PTEN (which only has protein phosphatase activity) in inhibiting the proliferation and migration of PSCs and collagen synthesis (Zhang et al., 2018). PTEN was shown to regulate cell cycle by affecting p27Kip1 and cyclinD1 in activated PSCs; this indicates a potential role of nuclear PTEN in the activation of PSCs. The activity of cyclin D1 is required for cell cycle G1/S transition. PTEN can negatively regulate the cell cycle by suppressing cyclin D1 in PSCs, which is consistent with lung fibroblasts (Geng et al., 2016) and hepatic stellate cells (An et al., 2016). The similar suppression ability of wildtype and mutant (G129E) suggests that PTEN mainly suppresses cyclin D1 via its protein phosphatase activity in PSCs. However, p27Kip1, which specifically binds to CDK-cyclin complexes to initiate cell cycle arrest, was upregulated by PTEN (Zhang et al., 2018). The role of PTEN in regulating cell cycle seems to be similar in different pro-fibrotic cell types. Besides, the protein expressions of BAX and Bcl-2 were up- and down-regulated, respectively, by PTEN-induced apoptosis of PSCs; thus, further studies are required to identify the step where mito-PTEN or the cellular localization changes of PTEN are involved in this process. In another study, miR-200a promoted the expression of PTEN and attenuated the TGF-β1-induced activation of PSCs and deposition of ECM in rat (Xu et al., 2017).

Some recent studies have shown that autophagy leads to the activation of PSCs (Xue et al., 2017; Li Z., et al., 2020). As a negative regulator of the PI3K-AKT-miTOR signaling pathway, PTEN is believed to play an important role in autophagy. However, the role of PTEN in regulating myophagy during activation of PSCs and the underlying mechanisms are largely unknown. A study revealed that PTEN inhibition can promote the expression of Mitofusin-2 (Mfn2) and improve mitophagic flux via AMP-activated protein kinase (AMPK)-cAMP-response element-binding protein (CREB) signaling (Li P., et al., 2020). Phosphorylation of Mfn2 has been shown...
to dissociate mitochondria from ER, inducing initiation of mitophagy. Intriguingly, PTEN and Mfn2 are both localized at the ER-mitochondrial contact site (de Brito and Scorrano, 2008; Bononi et al., 2013). Thus, further studies should assess whether the interaction between PTEN and Mfn2 at ER-mitochondrial contact plays a vital role in the activation of PSCs.

Activated PSCs are also key precursor cells for cancer-associated fibroblasts and produce a microenvironment that enhances malignancy in pancreatic cancer. Silencing of miR-21, which targets PTEN, was shown to alleviate ROS-induced activation, migration, and glycolysis of PSCs and to inhibit pancreatic cancer cells simultaneously (Yan et al., 2018). In pancreatic ductal adenocarcinoma (PDAC) stroma, blocking the Hedgehog signaling in stromal fibroblasts induced proliferation of tumor cells, which was caused by PTEN degradation and AKT activation. Therefore, decreased stromal PTEN is associated with reduced survival in PDAC patients (Pitarresi et al., 2018). The above results indicate the crucial role of PTEN in pancreatic fibrosis. Further studies are required to unravel the underlying mechanisms.

CONCLUSION AND PERSPECTIVES

It has been recognized that subtle variations in PTEN gene, PTEN expression, or PTEN protein level have enormous consequences in terms of susceptibility to digestive system cancers. Advances in biotechnology have helped enhance our understanding of the biological functions of PTEN. An increasing body of evidence indicates that PTEN loss or inactivity is one of the major causes of cellular dysfunction in a broad spectrum of non-neoplastic digestive diseases, such as infection, inflammation, metabolic abnormalities, and fibrosis. Though these diseases seem to be benign, their long-term existence or repeated occurrence may trigger carcinogenesis. Hence, early alterations in PTEN and the degree of these changes in non-neoplastic diseases may warn against occurrence of cancer.

Along with the discovery of canonical and non-canonical PTEN, multiple sites of cellular localization and various molecular interactions of this protein have been identified. However, the difference of PTEN cellular localization and the shuttling process of PTEN between cytosol and nucleus during the development of non-neoplastic digestive diseases is not well characterized. Especially, PTEN-Long can be secreted from cells and taken up by other cells; its localization in mitochondria has been found to suppress mitophagy in central nervous system diseases and kidney inflammation. However, the role and mechanism of PTEN-Long and the effect of the changes in its cellular localization on the development of non-neoplastic digestive diseases is not well understood. Hence, the molecular mechanisms for PTEN in the mitochondria and the nucleus in the context of non-neoplastic digestive diseases should be further investigated.

Clinical trials of PTEN-targeted therapies have been conducted in patients with cancer (Bang et al., 2019) and Alzheimer’s disease (Mohamed et al., 2019). Recent years have witnessed rapid advances in gene therapy and its application in clinical settings (Dunbar et al., 2018). In particular, the CRISPR/Cas9 gene-editing technology has provided researchers with revolutionary tools for gene therapy. However, gene therapies targeting PTEN are still in the animal experiment stage. Due to the difference between the in vivo and in vitro environment, and the discrepancy between species, the results obtained from the cell or animal models have some inherent limitations. However, no clinical trials involving PTEN targeting have been conducted in patients with non-neoplastic digestive diseases. As PTEN is a potential therapeutic target in the context of several benign diseases of the digestive system, more work is required to unravel the related molecular mechanisms. Translational research results into clinical application needs more time.

AUTHOR CONTRIBUTIONS

JH designed the manuscript. TH and XZ drafted the manuscript and drew the figures and table. SD and JH reviewed and edited the article. SD supervised the article. All authors read and approved the final manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China (grant no. 81470888).

REFERENCES

Alexandrova, I. M., Ishihara, M., Jung, D. Y., Friedline, R., Ko, H. J., Xu, M., et al. (2012). Cytoplasmic polyadenylation element binding protein deficiency stimulates PTEN and Stat3 mRNA translation and induces hepatic insulin resistance. PLoS Genet 8:e1002457. doi: 10.1371/journal.pgen.1002457

An, J., Zheng, L., Xie, S., Yin, F., Huo, X., Guo, J., et al. (2016). Regulatory effects and mechanism of adenovirus-mediated PTEN gene on hepatic stellate cells. Dig. Dis. Sci. 61, 1107–1120. doi: 10.1007/s10620-015-3976-2

Bang, Y. J., Kang, Y. K., Ng, M., Chung, H. C., Wainberg, Z. A., Gendreau, S., et al. (2019). A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. Eur. J. Cancer. 108, 17–24. doi: 10.1016/j.ejca.2018.11.017

Bettstetter, M., Berezowska, S., Keller, G., Walch, A., Feuchtinger, A., Slotta-Huspenina, J., et al. (2013). Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome. Hum.Pathol. 44, 829–836. doi: 10.1016/j.humpath.2012.08.005

Bian, E. B., Huang, C., Ma, T. T., Tao, H., Zhang, H., Cheng, C., et al. (2012). DNAMT1-mediated PTEN hypermethylation confers hepatic stellate cell activation and liver fibrogenesis in rats. Toxicol. Appl.Pharmacol. 264, 13–22. doi: 10.1016/j.taap.2012.06.022

Bononi, A., Bonora, M., Marchi, S., Misirroli, S., Poletti, F., Giorgi, C., et al. (2013). Identification of PTEN at the ER and MAMs and its regulation of Ca(2+) signaling and apoptosis in a protein phosphatase-dependent manner. Cell Death. Differ. 20, 1631–1643. doi: 10.1038/cdd.2013.77
Geng, J., Huang, X., Li, Y., Xu, X., Li, S., Jiang, D., et al. (2016). Phosphatase and tensin homolog deleted on chromosome 10 contributes to phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis via multiple pathways. *Exp. Biol. Med (Maywood)* 241, 157–165. doi: 10.1177/153537021660100

Geng, W., Zhou, G., Zhao, B., Xiao, Q., Li, C., Fan, S., et al. (2020). Lipirriginigen suppresses the activation of hepatic stellate cells via targeting miR-181b/PTEN axis. *Phymedecine* 66:153108. doi: 10.1016/j.phymed.2019.153108

Geybels, M. S., Fang, M., Wright, J. L., Qu, X., Bibikova, M., Klotzle, B., et al. (2017). PTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles. *Oncotarget* 8, 84338–84348. doi: 10.18632/oncotarget.20940

Gu, J., Tamura, M., Pankov, R., Danen, E. H., Takino, T., Matsumoto, K., et al. (1999). Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. *J. Cell Biol.* 146, 389–403. doi: 10.1083/jcb.146.3.2389

Gu, T., Zhang, W., Wang, G., Guo, J., Shen, W. H., and Yin, Y. (2011). CREB is a novel nuclear target of PTEN phosphatase. *Cancer Res.* 71, 2821–2825. doi: 10.1158/0008-5472.CAN-10-3399

Guldberg, P., thorStraten, P., Birck, A., Ahrenkiel, V., Kirschen, A., et al. (1997). Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. *Cancer Res.* 57, 3660–3663.

Guo, J., Dou, L., Meng, X., Chen, Z., Yang, W., Fang, W., et al. (2017). Hepatic MiR-29b-3p mediated glucose metabolism by directly targeting P65 to upregulate PTEN expression. *Sci. Rep.* 7:59899. doi: 10.1038/srep39899

Ha, H. L., and Yu, D. Y. (2010). HBx-induced reactive oxygen species activates hepatocellular carcinogenesis via dysregulation of PTEN/Akt pathway. *World J. Gastroenterol.* 16, 4932–4937. doi: 10.3748/wjg.v16.i39.4932

Hao, X. I., Xu, C. Z., Wang, J. T., Li, X. J., Wang, M. M., Gu, Y. H., et al. (2018). mir-21 promotes proliferation and inhibits apoptosis of hepatic stellate cells through targeting PTEN/P38/AKT pathway. *J. Recept. Signal.Transduct. Res.* 38, 455–461. doi: 10.1007/1075883.2019.158542

Heinrich, F., Chakravarthy, S., Nanda, H., Papa, P., Pandolfi, P. P., Ross, A. H., et al. (2015). The PTEN tumor suppressor forms homodimers in solution. *Structure* 23, 1952–1957. doi: 10.1016/j.str.2015.07.012

Hernández-Trejo, J. A., Suárez-Pérez, D., Gutiérrez-Martínez, I. Z., Fernandez-Vargas, O. E., Serrano, C., Candelario-Martínez, A. A., et al. (2016). The pro-inflammatory cytokines IFNγ/TNFα increase chromogranin A Positive neuroendocrine cells in the colonic epithelium. *Biochem. J.* 473, 3805–3818. doi: 10.1042/BC20160390

Hettinger, K., Vikhanskaya, F., Poh, M. K., Lee, M. K., de Belle, I., Zhang, J. T., et al. (2007). C-Jun promotes cellular survival by suppression of PTEN. *Cell Death Differ.* 14, 218–229. doi: 10.1038/sj.cdd.4401946

Hopkins, B. D., Fine, B., Steinbach, N., Endy, M., Rapp, Z., Shaw, J., et al. (2013). A secreted PTEN phosphatase that enters cells to alter signaling and survival. *Science* 341, 399–402. doi: 10.1126/science.1234907

Horie, Y., Suzuki, A., Kataoka, S., Sasaki, T., Hamada, K., Sasaki, J., et al. (2004). Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. *J. Clin. Invest.* 113, 1774–1783. doi: 10.1172/JCI20513

Hou, Z., and Quan, J. (2017). Hepatitis B virus X protein increases microRNA-21 expression and accelerates the development of hepatoma via the phosphatase and tensin homolog/phosphoinositide 3-kinase/protein kinase B signaling pathway. *Mol. Med. Rep.* 15, 3285–3291. doi: 10.3892/mmr.2017.7636

Howe, C., Mitchell, J., Kim, S. J., Im, E., and Rhee, S. H. (2019). Pten gene deletion in intestinal epithelial cells enhances susceptibility to *Salmonella Typhimurium* infection in mice. *J. Microbiol.* 57, 1012–1018. doi: 10.1007/s12275-019-9320-3

Im, E., Jung, J. Poouthalakis, C., and Rhee, S. H. (2014). Disruption of Pten speeds onset and increases severity of spontaneous colitis in Il10(-/-) mice. *Gastroenterology* 147, 667–679. doi: 10.1053/j.gastro.2014.05.034

Jeong, S. H., Kim, H. B., Kim, M. C., Lee, J. M., Lee, J. H., Kim, J. H., et al. (2018). Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer. *J. Cell. Investig.* 128, 1010–1025. doi: 10.1172/JCI95802

Ji, X. X., Ji, X. J., Li, Q. Q., Lu, X. X., and Luo, L. (2018). Rosiglitazone improves apoptosis and inflammation in lipopolysaccharide-induced human umbilical vein endothelial cells. *Med. Sci. Monit.* 24, 6200–6207. doi: 10.12659/MSM.910036

Jia, B., Yu, D., Yu, G., Cheng, Y., Wang, Y., Xi, Y., et al. (2018). Naringenin improves hepatitis C virus infection induced insulin resistance by increase PTEN expression via p53-dependent manner. *Biomed. Pharmacother.* 103, 746–754. doi: 10.1016/j.biopha.2018.04.110
Jiang, W., Liu, J., Dai, Y., Zhou, N., Ji, C., and Li, X. (2015). MiR-146b attenuates high-fat diet-induced non-alcoholic steatohepatitis in mice. *J. Gastroenterol. Hepatol.* 30, 933–943.

Khalid, A., Hussain, T., Manzoor, S., Saalim, M., and Khaliq, S. (2017). PTEN: a potential prognostic marker in virus-induced hepatocellular carcinoma. *Hum. Pathol.* 51, e11042317705754.

Kim, J., Kang, H. S., Lee, Y. J., Lee, H. J., Yun, J., Shin, J. H., et al. (2014). EGR1-dependent PTEN upregulation by 2-benzoyloxyxcinamaldehyde attenuates cell invasion and EMT in colon cancer. *Cancer Lett.* 349, 35–44. doi: 10.1016/j.cancerlet.2014.03.025

Kleiner, D. E., and Makhlouf, H. R. (2016). Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children. *Clin. Liver Dis.* 20, 293–312. doi: 10.1016/j.cld.2015.10.011

Kong, G., Zhang, J., Zhang, S., Shan, C., Ye, L., and Zhang, X. (2011). Upregulated microRNA-29b by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. *PLoS One* 6:e19518. doi: 10.1371/journal.pone.0019518

Kong, L., Wu, Q., Zhao, L., Ye, J., Li, N., and Yang, H. (2019). Effect of microRNA-27a-5p on apoptosis and inflammatory response of pancreatic acinar cells in acute pancreatitis by targeting PTEN. *J. Cell Biochem.* 120, 15844–15850. doi: 10.1002/jcb.28855

Kumar, P., Raeman, R., Chopyk, D. M., Smith, T., Verma, K., Liu, Y., et al. (2014). EGR1-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in adult hepatitis B virus transgenic mice. *Sci. Rep.* 7:2796. doi: 10.1038/s41598-017-03070-8

Lee, J. O., Yang, H., Georgescu, M. M., Di Cristofano, A., Maehama, T., Shi, Y., et al. (1999). Crystal structure of the PTEN tumour suppressor: implications for its phosphoinositide phosphatase activity and membrane association. *Cell* 99, 323–334. doi: 10.1016/S0092-8674(00)81663-3

Lee, Y. R., Chen, M., and Pandolfi, P. P. (2018). The functions and regulation of the PTEN tumour suppressor: new modes and prospects. *Nat. Rev. Mol. Cell Biol.* 19, 547–562. doi: 10.1038/s41580-018-0015-0

Lee, Y. R., Chen, M., and Pandolfi, P. P. (2018). The functions and regulation of the PTEN tumour suppressor: new modes and prospects. *Nat. Rev. Mol. Cell Biol.* 19, 547–562. doi: 10.1038/s41580-018-0015-0

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and pancreatic tumors. *Science* 273, 13375–13378. doi: 10.1126/science.273.22.13375

Managlia, E., Katzman, R. B., Brown, J. B., and Barrett, T. A. (2013). Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells. *Inflamm. Bowel Dis.* 19, 2051–2060. doi: 10.1097/MIB.0000000000000577

Manning, B. D., and Cantley, L. C. (2007). AKT/PKB signaling: navigating downstream. *Cell* 129, 1261–1274. doi: 10.1016/j.cell.2007.06.009

Matsutomo, M., Han, S., Kitamura, T., and Accili, D. (2006). Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. *J. Clin. Invest.* 116, 2464–2472. doi: 10.1172/JCI27047

Meng, Z., Jia, L. F., and Gan, Y. H. (2016). PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition. *Life Sci.* 103, 297–301. doi: 10.1016/j.lfs.2014.04.016

Mohamed, W. A., Salama, R. M., and Schaalan, M. F. (2019). A pilot study on the effect of lactoferrin on Alzheimer’s disease pathological sequelae: impact of the p-Akt/PTEN pathway. *Biomed. Pharmacother.* 111, 714–723. doi: 10.1016/j.biopha.2018.12.118

Mueller, S., Phillips, J., Onar-Thomas, A., Romero, E., Zheng, S., Wiencek, J. K., et al. (2012). PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. *Neuro. Oncol.* 14, 1146–1152. doi: 10.1093/neuonc/nos140

Nally, J. F. P., Kumar, N., Narayanan, K., and Palanimuthu, V. R. (2017). Long-term exposure to a butter-rich diet induces mild-to-moderate steatosis in Chang liver cells and Swiss albino mice models. *J. Basic Clin. Physiol.Pharmacol.* 28, 257–265. doi: 10.1515/jbcp-2016-0058
Ni, S., Wang, H., Zhu, X., Wan, C., Xu, J., Lu, C., et al. (2017). CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer. Oncotarget 8, 8010–8021. doi: 10.18632/oncotarget.14037

Niu, X., Fu, N., Du, J., Wang, R., Wang, Y., Zhao, S., et al. (2016). miR-1273g-3p modulates activation and apoptosis of hepatic stem cells by directly targeting PTEN in HCV-related liver fibrosis. FEBS Lett. 590, 2709–2724. doi: 10.1002/1873-4682.12309

Norén, E., Almer, S., and Söderman, J. (2017). Genetic variation and expression levels of tight junction genes identifies association between MAGI3 and inflammatory bowel disease. BMC Gastroenterol. 17:68. doi: 10.1186/s12876-017-0620-y

Norén, E., Mellander, M. R., Almer, S., and Söderman, J. (2018). Genetic variation and gene expression levels of tight junction genes indicates relationships between PTEN as well as MAGI and microscopic colitis. Dig. Dis. Sci. 63, 105–112. doi: 10.1007/s10620-017-4857-9

Papa, A., Wan, L., Bonora, M., Salmena, L., Hobbs, R. M., et al. (2015). Suppression of hepatocyte nuclear factor 4α by long-term infection of hepatitis B virus contributes to tumor cell proliferation. Int. J. Mol. Sci. 21:E948. doi: 10.3390/ijms21030948

Patireesi, R. J., Liu, X., Avendano, A., Thies, K. A., Sizemore, G. M., Hammer, A. M., et al. (2018). Disruption of stromal hedgehog signaling initiates RNF5-mediated proteasomal degradation of PTEN and accelerates pancreatic tumor growth. Life Sci. Alliance 1:e20180190. doi: 10.26508/lsa.20180190

Poliseno, L., Salmena, L., Zhang, J., Carver, B., Haveman, W. J., and Pandolfi, P. P. (2010). A coding-independent function of gene and pseudogene microRNAs regulates tumour biology. Nature 465, 1033–1038. doi: 10.1038/nature09144

Polytarchou, C., Hommes, D. W., Palumbo, T., Hatziapostolou, M., Koussiouma, M., Koukos, G., et al. (2015). miR-204 is Associated with progression of ulcerative colitis, and inhibition reduces development of colitis and colitis-associated cancer in mice. Gastroenterology 149, 981–992. doi: 10.1053/j.gastro.2015.05.057

Qian, Y. Y., Liu, Z. S., Yan, H. J., Yuan, Y. F., Levenson, A. S., and Li, K. (2018). Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease. J. Clin. Invest. 119, 3626–3636. doi: 10.1172/JCI93974

Song, L. B., Li, J., Liao, W. T., Feng, Y., Yu, C. P., Hu, L. J., et al. (2009). The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J. Clin. Invest. 119, 3626–3636. doi: 10.1172/JCI93974

Shen, S. M., Zhang, C., Ge, M. K., Dong, S. S., Xia, L., He, P., et al. (2019). PTENs and PTENβ promote carcinogenesis through WDR5 and H3K4 trimethylation. Nat. Cell Biol. 21, 1436–1448. doi: 10.1038/s41556-019-0409-z

Shen, W. H., Balaje, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., et al. (2007). Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128, 157–170. doi: 10.1016/j.cell.2006.11.042

Shi, Y., Wang, J., Chandarlapaty, S., Cross, J., Thompson, C., Rosen, N., et al. (2014). PTEN is a protein tyrosine phosphatase for IRS1. Nat. Struct. Mol. Biol. 21, 522–527. doi: 10.1038/nsmb.2828

Song, Y., Li, P., Qin, L., Xu, Z., Jiang, R., Ma, C., et al. (2021). CUL4B negatively regulates Toll-like receptor-triggered proinflammatory responses by repressing PTN transcription. Cell Mol. Immunol. 2021, 339–349. doi: 10.1038/s41423-019-0323-0

Stambolic, V., MacPherson, D., Sung, D., Lin, Y., Snow, B., Yang, Y., et al. (2001). Regulation of PTEN transcription by p53. Mol. Cell 8, 317–326. doi: 10.1016/s0197-2765(01)00323-9

Su, T., Ono, H., Suzuki, T., Sakai, G., Inukai, K., Katagiri, H., et al. (2014). Microbial hypoblastic PTEN modules hepatic insulin resistance independently of food intake in rats. Am. J. Physiol. Endocrinol. Metab. 307, E47–E50. doi: 10.1152/ajpendo.00361.2013

Sun, Y., Yu, M., Qu, M., Ma, Y., Zheng, D., Yue, Y., et al. (2020). Hepatitis B virus-activated PTEN β-catenin-c-Myc-signalingsenhances PD-L1 expression to promote immune evasion. Am. J. Physiol. Gastrointest. Liver Physiol. 318, G162–G173. doi: 10.1152/ajpgi.00197.2019

Tu, W., Yang, Y., Song, Y., and Zhu, W. (2019). Hepatitis B virus x protein accelerated the proliferation of hepatocellular carcinoma cell line through LncRNA SNHG20/PTEN pathway. J. Biochem. 165, 423–431. doi: 10.1093/ib/mwy120

Um, T. H., Kim, H., Oh, B. K., Kim, M. S., Kim, K. S., Jung, G., et al. (2011). aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J. Hepatol. 54, 939–947. doi: 10.1016/j.jhep.2010.08.021

Vazquez, F., Grossman, S. R., Takahashi, Y., Rokas, M. V., Nakamura, N., and Sellers, W. R. (2001). Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J. Biol. Chem. 276, 46827–46830. doi: 10.1074/jbc.C100556200

Vazquez, F., Ramaswamy, S., Nakamura, N., and Sellers, W. R. (2000). Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cell Biol. 20, 5010–5018. doi: 10.1128/mcb.20.14.5010-5018.2000

Vezza, T., Rodriguez-Nogales, A., Algieri, F., Utrilla, M. P., Rodriguez-Cabezas, M. E., and Galvez, J. (2016). Flavonoids in inflammatory bowel disease: a review. Nutrients 8:211. doi: 10.3390/nu8040211

Vukelić, I., Detel, D., Pučar, L. B., Potočnjak, I., Buljević, S., and Domitrivoić, R. (2018). Chlorogenic acid ameliorates experimental colitis in mice by suppressing signaling pathways involved in inflammatory response and apoptosis. Food Chem. Toxicol. 121, 140–150. doi: 10.1016/j.fct.2018.08.061

Wadhwia, R., Song, S., Lee, J. S., Yao, Y., Wei, Q., and Ajani, J. A. (2013). Gastric cancer-molecular and clinical dimensions. Nat. Rev. Clin. Oncol. 10, 643–655. doi: 10.1038/nrclinonc.2013.170

Walker, S. M., Leslie, N. R., Perera, N. M., Batt, I. H., and Downes, C. P. (2004). The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem. J. 365, 301–307. doi: 10.1042/BJ20031839

Wang, J., Xu, W., He, Y., Xia, Q., and Liu, S. (2018). LncRNA MEG3 impacts proliferation, invasion, and migration of ovarian cancer cells through regulating PTEN. Inflamm. Res. 67, 927–936. doi: 10.1007/s00011-018-1186-z

Wang, L., Cho, Y. L., Tang, Y., Wang, J., Park, J. E., Wu, Y., et al. (2018). PTEN-L is a novel protein phosphatase for ubiquitin dephosphorylation to inhibit PINK1-Parkin-mediated mitophagy. Cell Rep. 28, 787–802. doi: 10.1016/j.celrep.2018-05-056-0

Shen, S. M., Zhang, C., Ge, M. K., Dong, S. S., Xia, L., He, P., et al. (2019). PTENs and PTENβ promote carcinogenesis through WDR5 and H3K4 trimethylation. Nat. Cell Biol. 21, 1436–1448. doi: 10.1038/s41556-019-0409-z
Wang, S., Wang, L., Dou, L., Guo, J., Fang, W., Li, M., et al. (2016). MicroRNA-152 regulates hepatic glycogenosis by targeting PTEN. FEBS J. 283, 1935–1946. doi: 10.1111/febs.13713

Wang, Z., Li, N., Wang, B., and Lin, J. (2015a). Nonalcoholic fatty liver disease progression in rats is accelerated by splenic regulation of liver PTEN/AKT. Saudi J. Gastroenterol. 21, 232–238. doi: 10.4103/1319-3763.161641

Wang, Z., Wu, N., Tesfaye, A., Feinstone, S., and Kumar, A. (2015b). HCV infection-associated hepatocellular carcinoma in humanized mice. Infect. Agent Cancer 10:24. doi: 10.1186/s13027-015-0018-9

Williams, A. J., Doherty, E. S., Hart, M. H., and Grider, D. J. (2018). Distribution of Helicobacter pylori in the stomach of young children from rural Burkina Faso. J. Clin. Gastroenterol. 52, 231–239. doi: 10.1097/MCG.0000000000000703

Worby, C. A., and Dixon, J. E. (2014). PTEN. Annu. Rev. Biochem. 83, 641–669. doi: 10.1146/annurev-biochem-082411-113907

Wu, H. T., Chen, W., Cheng, K. C., Ku, P. M., Yeh, C. H., and Cheng, J. T. (2012). Oleic acid activates peroxisome proliferator-activated receptor δ to compensate insulin resistance in steatotic cells. J. Nutr. Biochem. 23, 1246–1250. doi: 10.1016/j.jnutbio.2011.07.006

Wu, Q., Li, Z., and Liu, Q. (2017a). Treatment with PTEN-Long protein inhibits hepatitis C virus replication. Virology 2017, 1–8. doi: 10.1016/j.virol.2017.08.002

Wu, Q., Li, Z., Mellor, P., Zhou, Y., Anderson, D. H., and Liu, Q. (2017b). The role of PTEN–HCV core interaction in hepatitis C virus replication. Sci. Rep. 7:3695. doi: 10.1038/s41598-017-03052-w

Wu, S. M., Li, T. H., Yun, H., Ai, H. W., and Zhang, K. H. (2019). miR-140-3p knockdown suppresses cell proliferation and fibrogenesis in hepatic stellate cells via PTEN-mediated AKT/mTOR signaling. J. Nutr. Biochem. 60, 561–569. doi: 10.3349/jn.2016.60.561

Wu, W., Yang, J., Feng, X., Wang, H., Ye, S., Yang, P., et al. (2013). MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal cancer cells. Mol. Cancer 12, 30. doi: 10.1186/1476-4598-12-30

Xie, S. R., An, J. Y., Zheng, L. B., Huo, X. X., Guo, J., Shih, D., et al. (2017). Effects of PTEN promotes gastric epithelial cell survival through the PLK1/PI3K/Akt pathway. Front. Immunol. 8, 2276. doi: 10.3389/fimmu.2017.02276

Xue, R., Yang, Z., Cao, X., Xu, W., Xie, C., Chen, J., Zhu, Y., et al. (2018). Phosphorylation of phosphatase and tensin homolog induced by Helicobacter pylori promotes cell invasion by activation of focal adhesion kinase. Oncol. Lett. 15, 1051–1057. doi: 10.3892/ol.2017.7430

Yang, Z., Cao, X., Xu, W., Xie, C., Chen, J., Zhu, Y., et al. (2018). Phosphorylation of phosphatase and tensin homologue induced by Helicobacter pylori promotes cell invasion by activation of focal adhesion kinase. Oncol. Lett. 15, 1051–1057. doi: 10.3892/ol.2017.7430

Yoshimi, A., Goyama, S., Watanabe-Okochi, N., Yoshiki, Y., Nannya, Y., Nitta, E., et al. (2011). PTEN inhibits tumor development in mice by regulating the NF-kB and TGF-β1 pathways. Mol. Biotechnol. 49, 35–43. doi: 10.1007/s12033-010-9289-2

Yoshiki, Y., Yoshiki, Y., Nannya, Y., Yoshiki, Y., Nannya, Y., Nitta, E., et al. (2011). PTEN inhibits tumor development in mice by regulating the NF-kB and TGF-β1 pathways. Mol. Biotechnol. 49, 35–43. doi: 10.1007/s12033-010-9289-2

Yoshiki, Y., Wang, M., Wang, L., Wang, J., Huang, H., et al. (2016). Inhibition of PTEN and induction of apoptosis in human myeloid leukemia K562 cells by miR-26a. Sci. Rep. 6, 20598. doi: 10.1038/srep20598

Zhang, J., Ning, X., Cui, W., Bi, M., Zhang, D., and Zhang, J. (2015). Transforming growth factor (TGF)-β-induced microRNA-216a promotes acute pancreatitis via Akt and TGF-β pathway in mice. Dig. Dis. Sci. 60, 127–135. doi: 10.1007/s10620-014-3261-9

Zhao, X., Wang, L., Li, O., Zhang, L., and Wang, S. (2019). MicroRNA-188-3p regulates the PTEN expression in hepatic stellate cells. Cell. Mol. Biol. 65, 281–287. doi: 10.1155/2019/739218
10 through microRNA-mediated control of DNA methylation—a novel mechanism suppressing liver fibrosis. *FEBS J.* 281, 88–103. doi: 10.1111/febs.12574

Zhu, Y., Hoell, P., Ahlemeyer, B., and Krieglstein, J. (2006). PTEN: a crucial mediator of mitochondria-dependent apoptosis. *Apoptosis* 11, 197–207. doi: 10.1007/s10495-006-3714-5

Zuo, M. L., Wang, A. P., Tian, Y., Mao, L., Song, G. L., and Yang, Z. B. (2019). Oxymatrine ameliorates insulin resistance in rats with type 2 diabetes by regulating the expression of KSRP, PETN, and AKT in the liver. *J. Cell Biochem.* 120, 16185–16194. doi: 10.1002/jcb.28898

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2021 He, Zhang, Hao and Ding. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*